Forgot your password?

Forgot your username?

database > company
Helsinn Healthcare S.A.
Biotech Specialty Pharma
Via Pian Scairolo 9, P.O Box 357
Pazzallo Lugano, (Lugano) 6915 Switzerland
phone:+41 (0) 91 985.21.21
fax:+41 (0) 91993.21.22
Symbol Private
Founded 1976
Employees 450
www.helsinn.com
Research Sector Biotech Specialty Pharma
Summary Description
Helsinn in-licenses early to late stage new chemical entities, completes their development from the performance of preclinical and clinical studies and of chemistry, manufacturing and control (CMC) development, to the filing for and the attainment of their market approval world-wide.
Management
Gabriele Braglia, Founder and Chairman; Gian Piero Brunello, Board Member; Giampaolo Henauer, Board Member; Luigi Caletti, CFO & Board Member; Franco De Vecchi, Group Board Member and US Chairman; Riccardo Braglia, Group CEO & Board Member; Giorgio Calderati, Group General Manager & Chief Operating Officer, Sergio Cantoreggi, Chief Scientific Officer, William Mann, Local CEO, US Business Pharma;
Keywords
Gastroenterology, pain, inflammation, cancer supportive care, licensing

Comment | Printable Version | Modify profile |
Updated: Nov. 22, 2011

Description
Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland and offices in Ireland and USA. Helsinn Group pinpoints innovative pharmaceutical products and medical devices in the early development phase and in- licenses the candidate by acquiring the world-wide rights. Helsinn?s leading position in its main business areas, Cancer Supportive Care, Pain and Inflammation, Gastrointestinal is reflected by the presence of the Group?s products in over 85 countries and with around 60 local marketing and commercial partners.
Products / Services
Helsinn?s leading position in its main business areas, Cancer Supportive Care, Pain and Inflammation, Gastrointestinal is reflected by the presence of the Group?s products in over 85 countries and with around 60 local marketing and commercial partners. Since its first product ? nimesulide ? was marketed in 1985, Helsinn has not only focused on scouting innovative products but also on creating a network of reliable partners, selected time after time according to their deep in-market knowledge and know-how, for the out-licensing and the distribution and sale of each of its products. Helsinn products are marketed worldwide through a tailor-made commercial network.
Technology / Differentiation
Helsinn Group pinpoints innovative pharmaceutical products and medical devices in the early development phase and in-licenses the candidate by acquiring the world-wide rights.